| Product Name | Encorafenib - API |
| Product Code | DA-E057-02 |
| Chemical name | Encorafenib |
| Synonyms | Methyl (S)-(1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate; Carbamic acid, N-[(1S)-2-[[4-[3-[5-chloro-2-fluoro-3-[(methylsulfonyl)amino]phenyl]-1-(1-methylethyl)-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]-1-methylethyl]-, methyl ester; Braftovi; |
| Impurity | NA |
| CAS Number | 1269440-17-6 |
| Alternate CAS # | NA |
| Molecular form | C22H27ClFN7O4S |
| Appearance | NA |
| Melting Point | NA |
| Mol. Weight | 540.01 |
| Storage | 2-8°C Refrigerator |
| Solubility | NA |
| Stability | NA |
| Category | impurities,metabolites,pharmaceutical standards,intermediates,Fine Chemicals |
| Boiling Point | NA |
| Applications | Encorafenib is a kinase inhibitor used to treat unresectable or metastatic melanoma with specific mutations. Encorafenib, also known as BRAFTOVI, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations Label. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and secretion. Mutations in this gene, most frequently the V600E mutation, are the most commonly identified cancer-causing mutations in melanoma, and have been isolated in various other cancers as well, including non-Hodgkin lymphoma, colorectal cancer, thyroid carcinoma, non-small cell lung carcinoma, hairy cell leukemia and adenocarcinoma of the lung 6. |
| Dangerous Goods Info | NA |
| References | NA |
| Extra Notes | NA |
| Documents (MSDS) | No Data Available |
| Keywords | NA |
